system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Biomarkers, Tumor, CDX2 Transcription Factor, Female, Gastric Mucins, Homeodomain Proteins, Humans, Immunohistochemistry, Male, Middle Aged, Mucin-2, Mucins, Neoplasm Invasiveness, Phenotype, Stomach Neoplasms.
user
Is cDX2 expression increased in gastric cancers with less invasiveness and intestinal mucin phenotype? Context: CDX2 is an intestinal transcription factor that might be involved in the regulation of proliferation and differentiation of intestinal epithelial cells. It is well known that both gastric and intestinal phenotypic cell markers are expressed in gastric cancers. The aims of this study were to analyze the CDX2 expression and its relationship with the patients' clinicopathological characteristics and the mucin phenotypes by performing immunohistochemistry. A total of 259 gastric cancer cases (122 early and 137 advanced cancers) were evaluated histologically and phenotypically. CDX2 expression was assessed by immunohistochemistry. Increased CDX2 expression correlated with a higher proportion of intestinal-type cancers of Lauren and early gastric cancers (p<0.001 and p<0.001, respectively) and a lower proportion of perineural invasion and lymph node metastasis (p<0.001 and p=0.003, respectively). Increased expressions of intestinal mucin (MUC-2, CD10) and decreased gastric mucin (MUC5AC) were associated with an increased CDX2 expression (p<0.001, p=0.045 and p=0.004, respectively). MUC6 expression was not associated with CDX2 expression. There was a significantly increased CDX2 expression in the intestinal phenotype compared with the other phenotypes (p<0.001).
assistant
These results suggest that CDX2 might be a useful marker in predicting the clinical outcome for patients with gastric cancers. Final Decision: yes